- Home
- IBRX vs EFSC Comparison
IBRX vs EFSC Comparison
Compare IBRX & EFSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBRX | EFSC |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | IBRX | EFSC |
|---|---|---|
| Price | $2.38 | $56.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $9.71 | ★ $65.67 |
| AVG Volume (30 Days) | ★ 11.5M | 133.0K |
| Earning Date | 11-04-2025 | 01-26-2026 |
| Dividend Yield | N/A | ★ 2.25% |
| EPS Growth | N/A | ★ 8.68 |
| EPS | N/A | ★ 5.13 |
| Revenue | $82,555,000.00 | ★ $646,694,000.00 |
| Revenue This Year | $667.18 | $20.14 |
| Revenue Next Year | $88.32 | $5.15 |
| P/E Ratio | ★ N/A | $11.07 |
| Revenue Growth | ★ 1025.95 | 9.31 |
| 52 Week Low | $1.83 | $45.22 |
| 52 Week High | $4.27 | $62.60 |
Technical Indicators
Market Signals| Indicator | IBRX | EFSC |
|---|---|---|
| Relative Strength Index (RSI) | 56.50 | 59.20 |
| Support Level | $2.17 | $55.09 |
| Resistance Level | $2.40 | $58.25 |
| Average True Range (ATR) | 0.15 | 1.31 |
| MACD | 0.03 | 0.32 |
| Stochastic Oscillator | 72.22 | 67.44 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About EFSC Enterprise Financial Services Corporation
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.